J. R. Gallimore

Natural history and outcome in systemic AA amyloidosis (2007)

Lachmann, H.J., Goodman, H.J.B., Gilbertson, J.A., Gallimore, J.R., Sabin, C.A., Gillmore, J.D., ...

Background: Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein (SAA) causes systemic AA amyloidosis, a serious complication of many chronic...

Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations (2006)

Lachmann, H.J., Sengül, B., Yavuzsen, T.U., Booth, D.R., Booth, S.E., Bybee, A., ...

Objective: To prospectively monitor inflammatory activity over a prolonged period in a cohort of Turkish patients with FMF, their healthy relatives and healthy controls and to relate this to their...

Targeting C-reactive protein for the treatment of cardiovascular disease (2006)

Pepys, M.B., Hirschfield, G.M., Tennent, G.A., Gallimore, J.R., Kahan, M.C., Bellotti, V., ...

Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases...

Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations (2006)

Lachmann, H. J., Engül, B., Yavuzen, T. U., Booth, D. R., Booth, S. E., Bybee, A., ...

Objective. To prospectively monitor inflammatory activity over a prolonged period in a cohort of Turkish patients with FMF, their healthy relatives and healthy controls and to relate this to their...

Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations (2006)

Lachmann, H. J., Engül, B., Yavuzen, T. U., Booth, D. R., Booth, S. E., Bybee, A., ...

Objective. To prospectively monitor inflammatory activity over a prolonged period in a cohort of Turkish patients with FMF, their healthy relatives and healthy controls and to relate this to their...

Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations (2006)

Lachmann, H. J., Sengül, B., Yavuzsen, T. U., Booth, D. R., Booth, S. E., Bybee, A., ...

Objective. To prospectively monitor inflammatory activity over a prolonged period in a cohort of Turkish patients with FMF, their healthy relatives and healthy controls and to relate this to their...

Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations (2006)

Lachmann, H. J., Engül, B., Yavuzen, T. U., Booth, D. R., Booth, S. E., Bybee, A., ...

Objective. To prospectively monitor inflammatory activity over a prolonged period in a cohort of Turkish patients with FMF, their healthy relatives and healthy controls and to relate this to their...

Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations (2006)

Lachmann, H. J., Engül, B., Yavuzen, T. U., Booth, D. R., Booth, S. E., Bybee, A., ...

Objective. To prospectively monitor inflammatory activity over a prolonged period in a cohort of Turkish patients with FMF, their healthy relatives and healthy controls and to relate this to their...

Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice (2005)

Hirschfield, G.M., Gallimore, J.R., Kahan, M.C., Hutchinson, W.L., Sabin, C.A., Benson, G.M., ...

The association between circulating concentrations of C-reactive protein (CRP) and future atherothrombotic events has provoked speculation about a possible pathogenetic role of CRP. However, we show...

Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability (2005)

Clapp, B.R., Hirschfield, G.M., Storry, C., Gallimore, J.R., Stidwill, R.P., Singer, M., ...

Background: Circulating concentrations of the sensitive inflammatory marker C-reactive protein (CRP) predict future cardiovascular events, and CRP is elevated during sepsis and inflammation, when...

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis (2002)

Pepys, M.B., Herbert, J., Hutchinson, W.L., Tennent, G.A., Lachmann, H.J., Gallimore, J.R., ...

The normal plasma protein serum amyloid P component (SAP) binds to fibrils in all types of amyloid deposits, and contributes to the pathogenesis of amyloidosis. In order to intervene in this process...

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis (2002)

Pepys, M.B., Herbert, J., Hutchinson, W.L., Tennent, G.A., Lachmann, H.J., Gallimore, J.R., ...

The normal plasma protein serum amyloid P component (SAP) binds to fibrils in all types of amyloid deposits, and contributes to the pathogenesis of amyloidosis. In order to intervene in this process...

Risk factors for coronary heart disease and acute-phase proteins. A population-based study (1999)

Danesh, J., Muir, J., Wong, Y-k, Ward, M., Gallimore, J.R., Pepys, M.B.

Aims Circulating levels of C-reactive protein and serum amyloid A protein increase markedly, and albumin levels fall, during the acute-phase response to tissue injury, infection and inflammation....